- Home
- CREV vs APLM Comparison
CREV vs APLM Comparison
Compare CREV & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- APLM
- Stock Information
- Founded
- CREV 2007
- APLM 2016
- Country
- CREV Ireland
- APLM United States
- Employees
- CREV N/A
- APLM N/A
- Industry
- CREV
- APLM Blank Checks
- Sector
- CREV
- APLM Finance
- Exchange
- CREV Nasdaq
- APLM Nasdaq
- Market Cap
- CREV 6.0M
- APLM 6.1M
- IPO Year
- CREV N/A
- APLM N/A
- Fundamental
- Price
- CREV $4.61
- APLM $5.78
- Analyst Decision
- CREV
- APLM
- Analyst Count
- CREV 0
- APLM 0
- Target Price
- CREV N/A
- APLM N/A
- AVG Volume (30 Days)
- CREV 447.3K
- APLM 47.5K
- Earning Date
- CREV 05-14-2025
- APLM 08-18-2025
- Dividend Yield
- CREV N/A
- APLM N/A
- EPS Growth
- CREV N/A
- APLM N/A
- EPS
- CREV N/A
- APLM N/A
- Revenue
- CREV $39,261,077.00
- APLM $198,000.00
- Revenue This Year
- CREV $40.76
- APLM $415.15
- Revenue Next Year
- CREV $86.18
- APLM N/A
- P/E Ratio
- CREV N/A
- APLM N/A
- Revenue Growth
- CREV 41.52
- APLM N/A
- 52 Week Low
- CREV $2.00
- APLM $4.47
- 52 Week High
- CREV $12.75
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- CREV 54.31
- APLM 46.89
- Support Level
- CREV $4.11
- APLM $5.41
- Resistance Level
- CREV $5.77
- APLM $6.38
- Average True Range (ATR)
- CREV 1.11
- APLM 0.49
- MACD
- CREV 0.02
- APLM -0.02
- Stochastic Oscillator
- CREV 24.26
- APLM 54.33
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.